Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PCNA | P12004 | 2/20 | 0.37 |
| ▸ | PPARG | P37231 | 8/20 | 0.36 |
| ▸ | PPARA | Q07869 | 8/20 | 0.36 |
| ▸ | PPARD | Q03181 | 3/20 | 0.36 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.35 |
| ▸ | LDHA | P00338 | 1/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.34 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL836728 | 0.87 | SLC7A5 (0.46) | PCNAPPARGPPARAPPARDSLC7A5 | |
| SCHEMBL10938101 | 0.87 | SLC7A5 (0.46) | PCNAPPARGPPARAPPARDSLC7A5 | |
| SCHEMBL169322 | 0.78 | SLC7A5 (0.55) | SLC7A5 | |
| SCHEMBL169321 | 0.78 | SLC7A5 (0.55) | SLC7A5 | |
| Methane SCHEMBL17267562 | 0.77 | SLC7A5 (0.53) | SLC7A5 | |
| SCHEMBL11198579 | 0.77 | SLC7A5 (0.47) | PCNAPPARGPPARAPPARDSLC7A5 | |
| SCHEMBL11198590 | 0.77 | SLC7A5 (0.47) | PCNAPPARGPPARAPPARDSLC7A5 | |
| SCHEMBL30716564 | 0.77 | PCNA (0.44) | PCNAPPARGPPARAPPARDSLC7A5 | |
| SCHEMBL7276725 | 0.73 | SLC7A5 (0.46) | PCNAPPARGPPARAPPARDSLC7A5 | |
| SCHEMBL31409225 | 0.73 | ESR1 (0.51) | PCNALDHA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024059776-A2 | ENHANCED DIFFERENTIATION OF PANCREATIC ISLET CELLS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-03-21 | — | — | WO | disclosed |
| EP-4271399-A1 | ENHANCED DIFFERENTIATION OF BETA CELLS | Vertex Pharmaceuticals Incorporated (US) | 2023-11-08 | — | — | EP | disclosed |
| WO-2023081884-A2 | STEM CELL DIFFERENTIATION AND CHEMICAL COMPOUNDS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-05-11 | — | — | WO | disclosed |
| WO-2022147056-A1 | ENHANCED DIFFERENTIATION OF BETA CELLS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-07-07 | — | — | WO | disclosed |
| EP-3990624-A1 | ENHANCED DIFFERENTIATION OF BETA CELLS | Vertex Pharmaceuticals Incorporated (US) | 2022-05-04 | — | — | EP | disclosed |
| EP-3833365-A1 | STEM CELL DERIVED ISLET DIFFERENTIATION | Vertex Pharmaceuticals Incorporated (US) | 2021-06-16 | — | — | EP | disclosed |
| CN-112246221-A | Polyion liquid covalent organic framework material, preparation method and application thereof | 徐州医科大学 | 2021-01-22 | — | — | CN | disclosed |
| WO-2020264072-A1 | ENHANCED DIFFERENTIATION OF BETA CELLS | SEMMA THERAPEUTICS, INC. (US) | 2020-12-30 | — | — | WO | disclosed |
| WO-2020033879-A1 | STEM CELL DERIVED ISLET DIFFERENTIATION | SEMMA THERAPEUTICS, INC. (US) | 2020-02-13 | — | — | WO | disclosed |
| WO-2016100898-A1 | SERUM-FREE IN VITRO DIRECTED DIFFERENTIATION PROTOCOL FOR GENERATING STEM CELL-DERIVED B CELLS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2016-06-23 | — | — | WO | disclosed |